Alkermes shares jump on news of another antipsychotic drug program; FDA sets PDUFA date on Orexigen's weight therapy;

@FierceBiotech: AbbVie adds a slate of $280M wagers on Seattle Genetics' "armed" antibody cancer tech. News | Follow @FierceBiotech

@JohnCFierce: Another SGLT2 drug arrives. Farxiga (dapagliflozin) from AZ. Release | Follow @JohnCFierce

@DamianFierce: Friendly reminder that there were 27 drugs approved last year and we wrote, like, 1,000 words on each. Report | Follow @DamianFierce

@EmilyMFierce: AstraZeneca has made 3 deals in past 5 days. Today with Immunocore: Story. Yesterday was Horizon: News. | Follow @EmilyMFierce

> Shares of Alkermes ($ALKS) popped 6% this morning after the company announced that it is adding a new program for the antipsychotic aripiprazole lauroxil, which is now in late-stage development as a once-monthly product. This new program will develop the therapy to be dosed once every two months. Release

> The FDA has set the PDUFA deadline on Orexigen's ($OREX) weight loss drug Contrave for June 10. Story

> Daiichi Sankyo, Virtici and Celdara Medical have inked a collaboration pact on new drugs. Release

> XTL Biopharmaceuticals ($XTLB) has reached a licensing agreement with Yeda Research and Development Company to develop hCDR1, a Phase II-ready asset for Systemic Lupus Erythematosus. Release

Medical Device News

@FierceMedDev: India's Forus hauls in $8M for portable eye-screening device. More | Follow @FierceMedDev

@MichaelGFierce: Durect, Impax tie up for a shingles patch to last 6 times as long as Lidoderm. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: FiercePharma has gone mobile! Check out the new app here. | Follow @EmilyWFierce

@GalenMoore: Former Hologic CEO Cascella lands at rival DySIS. Story | Follow @GalenMoore

> Foundation Medicine teams up with Novartis for cancer diagnostics. Item

> ArthroCare will pay $30M to finally settle up with the feds. Story

> Analysts have high hopes for St. Jude in 2014. Article

Pharma News

@FiercePharma: Dean Hart, ex-Takeda VP sales, joins consulting firm Delta Point (Press Release) | Follow @FiercePharma

@TracyStaton: Most-read report at FiercePharma Tuesday: Top 10 Drug Patent Losses of 2014. More from FiercePharma | Follow @TracyStaton

@EricPFierce: Put FiercePharma in your pocket. Get the mobile app for iOS or Android here, fiercepharma.com/mobile | Follow @EricPFierce

@CarlyHFierce: Welcome to our newest addition to the Fierce Life Sciences team, associate editor Emily Wasserman! You can find her at @EmilyWFierce. | Follow @CarlyHFierce

> Teva trumps Endo's offer for patchmaker NuPathe. Is a bidding war next? Story

> Japan files a criminal action against Novartis for 'exaggerated' Diovan advertising Story

> Roche, Teva and AstraZeneca are all said to be in the mix to buy Celltrion Story

> Forest nabs Aptalis for $2.9B in its CEO's latest move toward a turnaround Story

Drug Delivery News

> Gene delivery method 'hijacks' tumor blood vessels. More

> How a single nanoparticle delivers two drugs separately to kill cancer cells. Story

> Durect, Impax tie up for a shingles patch to last 6 times as long as Lidoderm. Article

> Vaccine nanoparticles offer shake-and-bake field delivery. Report

> Armed with cancer drugs, white blood cells become cancer-killing sticky bombs. News

> India to require all changes in delivery to be regulated as a new drug. Item

Diagnostics News

> Metabolon names two new investors in its $15M Series E. More

> Foundation Medicine deepens its Novartis ties with new deal. News

> Maverix Biomics hauls in $6M for gene sequencing software. Item

> The market for noninvasive prenatal tests could triple by 2019, analysts say. Story

> Kindstar partners with Israeli BioView to bring lung cancer Dx to Asia. Report

> SRI bags $4.5M NIH contract to set up metabolomics outpost. Article

Suggested Articles

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.

The series A round sets Abalos up to generate anti-tumoral virus strains and take them toward testing in humans.